Health Canada database synced November 3, 2026 · Prices from a published August 2026 retail audit Health Canada authorized generics only

Clinical pages are checked against the product monograph.

Four of our guides make clinical statements: how the generic compares with Ozempic, side effects, the Apo-Semaglutide product page and generic Wegovy. Each of those needs a licensed Canadian pharmacist to check every dose, indication, warning and interaction statement against the Health Canada product monographs before we can call it reviewed.

Until a review has actually happened, those pages say "Pharmacist review pending" in the byline and their structured data carries no reviewer. When a review is done, the page shows the reviewer's name, licence and the review date, all switched on together from one record. We do not show a review badge for a review that has not taken place, on any page, ever.

The clinical pages are still sourced line by line in the meantime: every health statement cites the product monograph, Health Canada or a peer-reviewed paper, and none of them gives personal dosing advice.

What a review covers

01
Doses and pens
Every dose, strength, concentration and pen statement is checked against the Canadian product monograph for that DIN.
02
Warnings
Side effects, serious risks and who should not take semaglutide are compared line by line with the monograph wording.
03
Equivalence claims
Anything about how the generic compares with Ozempic must match Health Canada's own wording, with its caveats.
04
Dated sign-off
The reviewer, licence and date go on the page only after the review is finished, and the page is rechecked when the monograph changes.